TENAX THERAPEUTICS, INC. (TENX)

NASDAQ · Pharmaceuticals & Biotech · Pharmaceutical Preparations

Price
$1.90
Day
-2.06%
Market cap
$71.11M

Close 2026-09-23.

The company

Our Strategy The key elements of our business strategy are outlined below. Efficiently conduct clinical development to establish clinical proof of principle in new indications, refine dosage levels and dosing strategies, conduct other required clinical and nonclinical testing as U.S. Federal Drug Administration (the “ FDA ” ) and other regulators may require, and continue Phase 3 testing of oral levosimendan, as our prioritized product candidate. Levosimendan and imatinib have already been approved and prescribed in other indications in many countries around the world. We are conducting clinical development with the intent to establish proof of beneficial activity in cardiopulmonary diseases in which these therapeutics would be expected to provide benefit to patients with diseases for which either no pharmaceutical therapies are approved at all, or in the case of pulmonary arterial hypertension, where numerous, expensive therapies generally offer a modest reduction of symptoms.

From Item 1: Our Strategy.

Institutional holders

Largest positions reported on Form 13F for the quarter ended 2026-06-30, by value.

Insider trades

Open-market buys and sales filed on Form 4, newest first. Grants, option exercises and tax withholding are left out.

Recent filings